HCV ALPHA (HCV RNA QUANTITATIVE AND HCV GENOTYPING

The HCV Alpha test is designed to assess the expression of a specific group of genes, often referred to as the interferon-stimulated genes (ISGs), which may influence a person’s response to antiviral therapy for Hepatitis C Virus (HCV) infection. This test plays a role in predicting treatment outcomes, especially in patients being considered for interferon-based therapies, although its usage is less frequent in the era of direct-acting antivirals (DAAs).

A blood sample is collected and subjected to RNA extraction, followed by quantitative PCR or gene expression profiling techniques. These methods evaluate the expression levels of several ISGs, providing insight into how strongly a person’s immune system is primed to respond to viral infections and therapy.

Higher expression levels of HCV alpha ISGs have been associated with a reduced response to interferon therapy, as it may indicate that the immune system is already maximally stimulated and less likely to respond to further interferon. On the other hand, lower baseline ISG levels have shown a better chance of achieving a sustained virological response (SVR). Although modern treatments have reduced the need for this test, it may still be used in specific cases, especially where interferon-based treatments are still practiced.

This test may be ordered for patients with chronic HCV infection who are being considered for interferon therapy or who have failed prior treatments. It can also be relevant in regions where access to newer antiviral drugs is limited.

 No special preparation is needed. However, patients should inform their physician of any ongoing antiviral therapy or underlying liver conditions that may affect gene expression results.